Imagine a world where cancer patients who lack effective treatment options can be cured. With our innovative cell therapy product, we are bringing this vision closer to reality. Our unique approach trains the patient’s own immune cells to target and eliminate cancer cells, providing a tailor-made treatment for each patient.
NEOGAP Therapeutics is a privately held biopharmaceutical company with the main focus on immuno-oncology.
Our pTTL cell therapy product, which targets neoantigens, is just one example of our cutting-edge technology at NEOGAP. Developed using our proprietary PIOR® and patented EpiTCer® technologies, pTTL generates T cells targeting neoantigens using immune cells from cancer patients as starting material.
NEOGAP is dedicated to advancing the field of personalised immunotherapy to combat cancer, starting with our focus on colorectal cancer. Our experienced team of professionals from academia and the pharmaceutical industry is committed to developing innovative solutions that are at the forefront of cutting-edge cancer research. Our pTTL cell therapy product is a testament to this dedication.
We also believe in the power of collaboration and are open to partnering with organisations that share our vision for advancing the field of personalised immunotherapy for cancer treatment.
Stay in the loop on our latest developments by reading our news.
We want to cure cancer that until now could not be cured
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.